Impact of Age and Genotype on Serum Concentrations of Valproic Acid and Its Hepatotoxic Metabolites in Chinese Pediatric Patients With Epilepsy
- 25 February 2020
- journal article
- research article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 42 (5) , 760-765
Abstract
Background The aim of the study was to investigate how age and genetic polymorphisms of UGT1A6 and UGT2B7 contribute to the concentrations of valproic acid (VPA) and its hepatotoxic metabolites in Chinese pediatric patients with epilepsy. Methods A total of 122 children with epilepsy were genotyped at 19T>G, 541A>G, and 552A>C in UGT1A6 and -161C>T and 802C>T in UGT2B7 using the polymerase chain reaction-restriction fragment length polymorphism method or direct sequencing method. The concentrations of VPA, 4-ene-VPA, and 2,4-diene-VPA were simultaneously determined using ultra-performance liquid chromatography-tandem mass spectrometry. Results Significant association was observed between the UGT2B7 802C>T genotype and dose-adjusted concentrations of VPA, 4-ene-VPA, and 2,4-diene-VPA. The younger children had increased concentrations of the hepatotoxic metabolites and decreased levels of VPA. The allele status of UGT2B7 802C>T had no influence on the metabolite ratios within age groups but showed a significant difference among the age groups. Conclusion The present study suggests that UGT2B7 802C>T polymorphism and age are factors affecting the concentrations of dose-adjusted VPA and its metabolites. No genotype-related differences were noted in the metabolite ratios of 4-ene-VPA and 2,4-diene-VPA within age-assigned groups. Therefore, careful administration is particularly necessary for younger patients who are UGT2B7 802C>T poor metabolizers.Keywords
This publication has 22 references indexed in Scilit:
- Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patientsToxicology Mechanisms and Methods, 2010
- Assessment of the quality and quantity of genomic DNA recovered from canine blood samples by three different extraction methodsResearch in Veterinary Science, 2008
- Gene expression profiles of murine fatty liver induced by the administration of valproic acidToxicology and Applied Pharmacology, 2007
- The Role of Pharmacogenetics in the Metabolism of Antiepileptic DrugsClinical Pharmacokinetics, 2007
- Contribution of CYP2C9, CYP2A6, and CYP2B6 to Valproic Acid Metabolism in Hepatic Microsomes from Individuals with the CYP2C9*1/*1 GenotypeToxicological Sciences, 2006
- Valproic Acid I: Time Course of Lipid Peroxidation Biomarkers, Liver Toxicity, and Valproic Acid Metabolite Levels in RatsToxicological Sciences, 2005
- Human UGT1A6 pharmacogeneticsPharmacogenetics, 2004
- Developmental Pharmacology — Drug Disposition, Action, and Therapy in Infants and ChildrenNew England Journal of Medicine, 2003
- Urinary Metabolites of Valproic Acid in Epileptic Patients.Biological and Pharmaceutical Bulletin, 1998
- Associations Between Risk Factors for Valproate Hepatotoxicity and Altered Valproate MetabolismEpilepsia, 1992